Caligan Partners LP

Q4 2024 13F Holdings

  • Location
    new york, NY
  • Num holdings

    14

  • Value ($000)

    $394,876

  • Date Filed
    02/14/2025
  • Form type
    13F-HR
  • CIK
    0001727492
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2024 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
LQDA
LQDA

LIQUIDIA CORPORATION

COM NEW
53635D202
$115.53 M
29 %

8,118,592

VRNA
VRNA

VERONA PHARMA PLC

SPONSORED ADS
925050106
$66.73 M
17 %

1,436,878

EX9
EX9

EXELIXIS INC

COM
30161Q104
$50.81 M
13 %

1,525,730

EOLS
EOLS

EVOLUS INC

COM
30052C107
$29.72 M
8 %

2,692,388

ANIK
ANIK

ANIKA THERAPEUTICS INC

COM
035255108
$23.62 M
6 %

1,435,130

BCRX
BCRX

BIOCRYST PHARMACEUTICALS INC

COM
09058V103
$22.53 M
6 %

2,995,932

AGIO
AGIO

AGIOS PHARMACEUTICALS INC

COM
00847X104
$20.58 M
5 %

626,280

SAGE
SAGE

SAGE THERAPEUTICS INC

COM
78667J108
$16.58 M
4 %

3,052,538

YMAB
YMAB

Y-MABS THERAPEUTICS INC

COM
984241109
$13.84 M
4 %

1,767,982

MLYS
MLYS

MINERALYS THERAPEUTICS INC

COM
603170101
$12.45 M
3 %

1,011,155

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 14